Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
2005-09-06
2005-09-06
Kunz, Gary (Department: 1616)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C424S046000, C424S043000, C424S489000, C514S558000, C514S002600
Reexamination Certificate
active
06939534
ABSTRACT:
A method of treating pulmonary hypoplasia in infants has been developed, wherein epidermal growth factor (EGF) is administered to the pulmonary system of an infant in need of treatment thereof. The EGF is administered as an aerosol or dry powder directly to the pulmonary tree, or into the amniotic fluid before birth if a situation such as oligohydramnios is recognized pre-term. The method can also be used to treat persistent pulmonary hypertension of the newborn. A hydrophobic angiotensin I-converting enzyme (ACE) inhibitor such as ramipril can also be used for the oral treatment of persistent pulmonary hypertension of the newborn.
REFERENCES:
patent: 4849350 (1989-07-01), Yoshio et al.
patent: 4959353 (1990-09-01), Brown et al.
patent: 5230884 (1993-07-01), Evans et al.
patent: 5654007 (1997-08-01), Johnson et al.
patent: 2002/0072540 (2002-06-01), Larsson et al.
patent: WO 97/36574 (1997-10-01), None
Abraham et al, Importance of Angiotensin-Converting Enzyme in Pulmonary Hypertension, Cardiology 1995; 86 (suppl 1):9-15.
Zanen, et al., “The optimal particle size for parasympathicolytic aerosols in mild asthmatics,”J. Int. J. Pharm.114: 111-115 (1995).
Adjei, et al., “Pulmonary delivery of peptide drugs: effect of particle size on bioavailability of leuprolide acetate in healthy mate volunteers,” Pharm. Res. 7: 565-569 (1990).
Gonda, “Physico-Chemical Principles in Aerosol Delivery,” in Topics in Pharmaceutical Sciences (Crommelin, et al., eds.) Medpham Scientific Publishers: Stuttgart, pp. 95-115 (1992).
Hofmann, et al., “Epidermal growth factor (EGF) concentrations in amniotic fluid and material urine during pregnancy,” Acta Obstet Gynecol Scand 69(3): 217-221 (1990).
Maraschin, et al., “Toxicological evaluation of u-hEGF,” Toxicol Pathol. 23: 356-366 (1995).
Miettinen, et al., “Impaired lung branching morphogenesis in the absence of functional EGF receptor,” Dev Biol 186: 224-236 (1997).
Plopper, et al., “Acceleration of alveolar type II cell differentation in fetal rhesus monkey lung by administration of EGF,” Am. J. Physiol 262(3.1): L313-L321(1992).
Rudt, et al., “In vitro phagocytosis assay of nano- and microparticles by chemiluminescence. I. Effect of analytical parameters, particle size and particle concentration,” J. Controlled Release 22: 263-272 (1992).
Sundell, et al., “Effects of epidermal growth factor on lung maturation in fetal lambs,”Am. J. Pathol.100: 707-725 (1980).
Tabata, et al., “Macrophage phagocytosis of biodegradable microspheres composed of L-lactic acid/glycolic acid homo- and copolymers,”J. Biomed. Mater. Res.22: 837-858 (1988).
Visser, “Van der Waals and other cohesive forces affecting powder fluidization,”Powder Technology58: 1-10 (1989).
Yoshimura, et al., “Effect of epidermal growth factor on lung growth in experimental fetal pulmonary hypoplasia,”Early Hum Dev57: 61-69 (2000).
GenoMed, LLC
Haghighatian Mina
Sonnenschein Nath & Rosenthal LLP
LandOfFree
Method to treat pulmonary hypoplasia in the newborn does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method to treat pulmonary hypoplasia in the newborn, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method to treat pulmonary hypoplasia in the newborn will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3427752